Spero Therapeutics IncSPRO
Price$1.26Intrinsic value$1.6128% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $12.6M+3,289.2% YoYTTM through 30 Jun 2026
Net Income $7.4MTTM through 30 Jun 2026
Free Cash Flow $7.3MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin51.2%
Operating Margin-2,921.7%
Net Margin58.7%

Returns

28.8%ROE
22.2%ROA
28.9%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.12x
Net Debt-$53.7Mnet cash position
Cash & Equivalents$50.8M

Quality Metrics

Altman Z-Score-5.27
Piotroski F-Score5 / 9
FCF Margin58.1%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $66.8M
Diluted EPS$0.14TTM
'21'23'24'25
FY2025: $0.15

Dividend

No dividend

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.